Do Kim
Stock Analyst at Piper Sandler
(2.17)
# 2,594
Out of 4,670 analysts
98
Total ratings
47.83%
Success rate
4.42%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $34.01 | +85.24% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $18.25 | +152.05% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $450.97 | -34.36% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $90.19 | +24.18% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $20.84 | +317.47% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $4.61 | +398.92% | 2 | Jan 19, 2023 | |
| AFMD Affimed | Maintains: Overweight | $70 → $60 | $2.62 | +2,190.08% | 6 | Dec 12, 2022 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $26.04 | -23.20% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $14.93 | +188.01% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $35.61 | -10.14% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $22 | $2.76 | +697.10% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $29.92 | -36.50% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $2.80 | +471.43% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $244.89 | -24.46% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $18.38 | +4,796.63% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $49.00 | -28.57% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $2.29 | +773.36% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $34.01
Upside: +85.24%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $18.25
Upside: +152.05%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $450.97
Upside: -34.36%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $90.19
Upside: +24.18%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $20.84
Upside: +317.47%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $4.61
Upside: +398.92%
Affimed
Dec 12, 2022
Maintains: Overweight
Price Target: $70 → $60
Current: $2.62
Upside: +2,190.08%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $26.04
Upside: -23.20%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $14.93
Upside: +188.01%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $35.61
Upside: -10.14%
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $2.76
Upside: +697.10%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $29.92
Upside: -36.50%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $2.80
Upside: +471.43%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $244.89
Upside: -24.46%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $18.38
Upside: +4,796.63%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $49.00
Upside: -28.57%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $2.29
Upside: +773.36%